Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2024 09:00 ET | Source: Amydis, Inc.

Amydis to Present First Ocular Tracer Designed to Detect Transthyretin Amyloidosis (ATTR) at AAOOP Conference

Amydis is developing a topical eye test to potentially transform early diagnosis of amyloidosis and enable more people to benefit from available drugs
November 14, 2023 07:00 ET | Source: Amydis, Inc.

Amydis Receives $3.4 million NIH Commercialization Readiness Pilot Grant Award to Map Heterogeneity of Alzheimer’s Diseases in Human Clinical Trial Using Novel Retinal Tracer

Amydis Receives $3.4 million NIH Grant Award to Map Heterogeneity of Alzheimer’s in Human Clinical Trial Using Novel Retinal Tracer
November 02, 2023 07:00 ET | Source: Amydis, Inc.

Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Beta

Amydis announces Phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients.
February 21, 2023 05:00 ET | Source: Amydis, Inc.

Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial

SAN DIEGO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable imaging of disease biomarkers in the eye, today...
October 27, 2022 07:00 ET | Source: Amydis, Inc.

Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic drug candidates targeting molecular biomarkers in the eye, today...
September 22, 2022 07:00 ET | Source: Amydis, Inc.

Amydis Announces Enrollment of First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Disease

SAN DIEGO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic drug candidates targeting CNS biomarkers in the eye, today...
August 18, 2022 07:00 ET | Source: Amydis, Inc.

Amydis Receives NIH Grant Award to Develop a Novel TDP-43 Retinal Tracer in Patients with ALS and FTD

SAN DIEGO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
April 04, 2022 07:00 ET | Source: Amydis, Inc.

Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board

SAN DIEGO, April 04, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a healthcare company developing a new class of molecular retinal diagnostics and digital biomarkers to accelerate the early detection and...
December 06, 2021 07:00 ET | Source: Amydis, Inc.

Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS

SAN DIEGO, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a biotechnology company developing novel ocular contrast agents (“tracers”) targeting CNS biomarkers in the eye, today announced the...
October 11, 2021 07:00 ET | Source: Amydis, Inc.

Amydis Awarded $3 Million NIH Grant to Explore Novel Alpha Synuclein Retinal Tracer in Non-human Primate Models of Parkinson’s Disease and Multiple System Atrophy

SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...

Next Page keyboard_arrow_right